Xaira Therapeutics

Xaira Therapeutics represents a significant convergence of biotechnology and artificial intelligence, structured to overhaul the conventional drug discovery and development pipeline. The company launched in April 2024, emerging from stealth with over $1 billion in committed capital, one of the largest initial funding rounds in biotech history. This substantial financial backing was co-led by ARCH Venture Partners and Foresite Labs, with a syndicate of prominent investors including Sequoia Capital, Lux Capital, and NEA. The venture was jointly incubated by ARCH Venture Partners and Foresite Labs.

The company is helmed by CEO Dr. Marc Tessier-Lavigne, a distinguished neuroscientist and executive with a background that bridges high-level academia and the biopharmaceutical industry. His prior roles include serving as president of both Stanford University and Rockefeller University, as well as Chief Scientific Officer at Genentech. Tessier-Lavigne co-founded Xaira alongside Nobel Laureate Dr. David Baker, director of the Institute for Protein Design (IPD) at the University of Washington, and Dr. Hetu Kamisetty, who serves as CTO and previously worked at Meta and the IPD. The leadership team is further strengthened by executives with experience from Genentech and Interline Therapeutics.

Xaira’s core business revolves around a three-pronged strategy: advancing machine learning research to decipher complex biology, generating expansive, high-quality biological data to train its AI models, and developing a pipeline of therapeutic products. The company’s technological foundation is built upon the groundbreaking work from Dr. Baker's IPD lab, particularly the generative AI models RFdiffusion and RFantibody, which can design novel proteins and antibodies from scratch. By leveraging these models, Xaira aims to design molecules for "undruggable" targets, which have been resistant to traditional therapeutic approaches. To power its AI, the company integrates vast, multidimensional datasets, incorporating technologies and personnel spun out from Illumina's functional genomics R&D and a proteomics group from Interline Therapeutics. This allows every experiment to become a data-generation opportunity, creating a feedback loop that continuously refines the predictive accuracy of its biological foundation models.

The company operates in the highly competitive AI-driven drug discovery market, positioning itself against other well-funded startups. Its business model is centered on creating and advancing its own pipeline of differentiated therapeutics across multiple modalities, rather than solely providing a service platform. Initially, the focus appears to be on protein-based antibody drugs, with the goal of expanding to other modalities. By engineering novel medicines and addressing the high failure rate of traditional drug development, Xaira aims to deliver more effective therapies to patients faster. Keywords: AI drug discovery, generative AI, protein design, machine learning in biology, therapeutic development, biotechnology, RFdiffusion, undruggable targets, computational biology, drug development pipeline, Marc Tessier-Lavigne, David Baker, ARCH Venture Partners, Foresite Labs, antibody design, proteomics, functional genomics, de novo protein design, biological foundation models, pharmaceutical AI, molecular engineering, therapeutics, preclinical development